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Summary Cutaneous atrophy arising irom prolonged use of potent topical corticosteroids has long been a
concern. Thus, it would be advantageous to lind an agent which protects against atrophy produced
by corticosteroids but at the same time does not impair their anti-intlammatory effects. Recent work
shows that topical all-fruMs retinoic acid (tretinoin) prevents skin atrophy in mice treated with topical
corticosleroids. but such studies have nol been performed in humans. We performed an 8-week
clinical, histoiogical and biochemical study to test the ability of tretinoin to enhance efficacy and
inhibit atrophogenicity of topical corticosteroids. when used in the treatment of psoriasis. In each of
20 psoriasis patients, one plaque, and its perilesional skin, was trealed once daily with betametha-
sone dipropionate and tretinoin ()'1%. and one plaque, and its perilesional skin, treated with once
daily betamethasone dipropionate and tretinoin vehicle. There was no difference in the speed or
degree of improvement in plaques treated with either the topical corticosteroid/tretinoin combina-
tion or with corticosteroid alone. Ijght microscopy revealed a 19% reducti(Hi in epidermal thickness,
in corticosteroid-treated perilesional skin, as compared with a slight (l'Xil increase in corticosteroid/
tretinoin-treated perilesional areas (P = {){)fi7|. Western blot analysis showed a 55% reduction in
procollagen I aminopropeptide in periiesional skin treated with corticosteroid alone, as compared
with a 45% reduction in corticosteroid/tretinoin-treated perilesionai skin. These data indicate that
the addition of tretinoin does not impair the efficacy of a topical corticosteroid, in the treatment of
psoriasis, and partially ameliorates epidermal atrophy produced hy the topical corticosteroid.
Topical corticosteroids are helpful for the treatment of
inflammatory dermatoses but their prolonged use may
be associated with cutaneous atrophy. Studies in mice
have demonstrated that concurrently applied all-tra?is
retinoic acid (trctinoini may prevent cutaneous atrophy
produced by topical corticosteroids.^ Lesnik ct ai~ have
demonstrated that tretinoin will prevent corticosteroid-
induced skin atrophy in hairless mice, hut without
impairment of corticosteroid anti-inflammatory proper-
ties. Results of another study^ are also compatible with
tbis observation, as tretinoin does not alter the vaso-
constrictive properties of topical corticosteroids in
normal human skin. Atopic dermatitis also responds
well to a combination of tretinoin and a mid-potency
topical steroid, without any increased irritation."^
Thus far. no controlled study in humans bas assessed
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the ability of tretinoin to. either, protect against
corticosteroid-induced cutaneous atrophy or enhance
the anti-inflammatory properties of corticosteroids. To
address these questitins. we investigated the ability of
topical tretinoin to prevent atrophy of surrounding
psoriatic skin during treatment with a topical cortico-
sleroid. and to enhance the efficacy of a midpotency




Twenty, healthy psoriatic patients (17 men. three
women; age range 25-70. mean age 46 years), each
with al least three stable psoriatic plaques of similar
severity and size, were entered into an 8-week, double-
blind vehicle-controlled study. No topical or oral treat-
ments, including ultraviolet radiation, other than bland
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emollients, were allowed within the 4 weeks preeeding
(he study, or during the study itself. Pregnant and
nursing women were excluded. All patients gtive writ-
ten informed consent, and the protocol was approved by
ihe institutional review board of the University of
Michigan Medical Center.
Three, clinically similar, psoriatic plaques were
chosen, on each patient. One plaque remained
unlreated and served as a control. The other two
plaques were treated each morning with a mid-potency
topical corticosteroid. i)-05% betamethasone dipropio-
nate cream (BD: U-05% Diprosone. Schering Corpora-
lion. Kenilworth, New Jersey. U.S.A.) and were
randomized to evening treatment with either {)-l%
tretinoin eream (Retin-A"^'. Ortho Pharmaceutical Cor-
poration. Raritan. New Jersey. U.S.A.) or colour-
matched vehicle cream (Ortho). Each study plaque
was a minimum of 5 cm in diameter, to ensure suilicient
biopsy area, and all treatments were applied to the
active plaque and to 5 em of uninvolved perilesional
skin. No study drugs were applied on the evening
before, or on the morning of. scheduled clinic visits.
All patients recei\'ed a mild emollient to be used, when
needed, for skin irritation or dryness. As all dispensed
tubes were identical in appearance, both investigators
and patients were unaware of the treatment group to
which each plaque was assigned. The sample sizes were
chosen to provide a statistical power of approximately
()-80 to detect a mean difference of 1 5 /im in epidermal
thickness, at the end of therapy, between BD/tretinoin
and Bl)/vehicle at a type I error rate of 0-()5, for a two-
sided paired comparison.
Clinical evahiatfous
Clinieal evaluations were performed at baseline, and at
weeks 1. 2. 4. 6 and 8 of therapy. One investigator
(AJM) evaluated all patients at ali visits. At the baseline
visit only, an overall evaluation of the severity of
psoriasis for all three plaques was performed, using a
li\'e-p{)int scale where 1 indicates no psoriasis: 2. mild:
5. moderate: 4. severe and 5, very severe. At both
baseline and follow-up visits, scaling, erythema and
plaque elevation were each assessed for eaeh plaque
on a nine-point. 0-8 scale. At follow-up visits only, a
global evaluation, compared with baseline, for all
plaques, was performed on a seven-point scale with 1
indicating markedly worse: 2. worse: 3, slightly worse:
4, no change: 5. slightly improved: fi, improved: and 7.
markedly improved. Also, skin atrophy of all three
plaques, and their corresponding perilesional skin.
was evaluated on a six-point scale with 1 indicating
none: 2, trace: 3. mild: 4. moderate: S. marked: and 6,
severe.
Side-effects
At each visit, cutaneous side-effects at all treatment
sites, and their corresponding perilesional skin, were
evaluated by measuring erythema, peeling, itching,
burning/stinging, depression, striae, wrinkling and
telangiectasia. using the aforementioned six-point
scale. Eor cutaneous effects, only increases of two or
more units, over baseline, at two or more visits, were
evaluated statistically.
Lifllil microscopii
Two. 4 mm punch biopsies, one from the plaque and
one from perilesional skin of each treated plaque, were
obtained at baseline and after 8 weeks of treatment. The
biopsies were immediately bisected, and one-half placed
in 10% neutral-buffered formalin, embedded in paraffin,
sectioned, and stained with haematoxylin and eosin.
The other half of the specimen was either placed in
optimal cutting temperature medium (OCT. Miles
Laboratories. Elkhart. Indiana. U.S.A.) and snap frozen
in liquid nitrogen, or directly frozen in liquid nitrogen,
and stored at —70'^C until processed for Western blot
analysis. The investigator who analysed the histological
specimens (L)I"| was not aware of either the patient's
treatment or the timing of the biopsy. Stratum corneum
compaction, granular cell layer thickness, spongiosis
and dermal inflammation were assessed using a semi-
quantitative scale ranging from 0 to 4. where 0 was no
evidence of parameter, and 4 was maximum expression.
Epidermal thickness in /im was measured from the
top of the gratiular layer to the epidermal basement
membrane, in five inter rete-ridge spaces per specimen.
Western hlot analysis
Procollagen was extracted from skin biopsies, as
described,''*' and supernatants prepared for Western
blot analysis of type I procollagen aminopropeptide
(pNcoI I). Incubations were performed with affinity
purified anti-pNcol I polyclonal antibody (a generous
gift of Drs |. and L.Ristelli, University of Oulu, Finland)
overnight at 4'̂ C, and pNcol I identified by comigration
with authentic standards (a generous gift of Prof.
M.Lapiere, University of Liege. Belgium). Radioactivity
in the bands was measured by Phosphorimager
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(Molecular Dynamics), and results expressed as counts
per minute/unit protein.
Statistical analysis
Comparisons of the change from baseline in clinical and
histological parameters, between sites treated with cor-
ticosteroid alone, vs. those treated with corticosteroid
plus tretinoin. were made with the paired t-test. The
nonparametric Wilcoxon signed-rank test was used to
compare changes in pNcol I levels, as determined by
Western blot analysis due to the non-normal distribu-
tion of the data. All P values were two-tailed. Summary
statistics are expressed as means ± standard error of the
mean (SEM). The data were analysed with the use of the
Michigan Interactive Data Analysis System (MIDAS), a
statistical software package developed by the Centre for
Statistical Consultant and Research, at the University of
Michigan.
Results
Seventeen of 20 patients completed the 8-week study,
although only 16 of them had the final 8-week biopsy
performed. Two patients dropped out. one after week 4,
and one after week 6. because of personal responsibil-
ities. One patient discontinued the study at week 1,
secondary to a protocol violation of applying topical
study creams to the control site. One patient refused
biopsy upon completion of the study. Therefore, clinical











Figure 1. Global response to trcatmctil of psoriasis plaques witl i
bt'lamethasonc dipropionate (BIJ) vehicle (broken linesl, BD/trelinoin
(solid lines) or no treatment (alternate, long-short dashed lines).
Circles, squares and triangles with error bars indicate means ±
standard error (SE). n = t 7 . No statistically significant difference
was noted in the rate or overall Improvement of BI)/vehicle treated
plaques vs. Ibe BD/tretinoin treated plaques.
Clinical findings
Assessment of the clinical global response revealed that
all patients had at least slight improvement in their
psoriasis, at both treated sites, after 8 weeks of treat-
ment. Sites treated with BD/tretinoin showed a marked
improvement in nine (S3%) patients, an improvement in
four (24%) and H slight improvement in four. Similarly,
sites treated with BD/vehicle demonstrated a marked
improvement in nine (53%) patients, an improvement
in three (18%). and a slight improvement in five (29%).
Control, untreated sites, showed a slight improvement in
five (29%) patients, no change in 10 (59%). and a
worsening in two (12%). The speed of improvement
was no different between the two treatment sites. Thus,
the two treatments were equally efficacious and the
addition of tretinoin conferred no added advantage in
efficacy to BD for psoriasis treatment {Fig. 1). Further-
more, at completion of the stndy (week 8), no clinical
atrophy was noted in any perilesional area.
Side-effects
Cutaneous reactions were characterized principally by
erythema and scaling. Erythema and/or scaling of at
least moderate severity occurred in six of 19 (32%)
patients, in the tretinoin-treated plaques, and in one of
19 (5%) patients, in the vehicle-treated plaques, during
the study.
Histological findings
In perilesional skin treated with BD/vehicle, the epi-
/̂̂ .̂/̂ .'̂ .~--.
BL 8 Wks BL 8 Wks
I'igure 2. Overall chiinge from baseline ( B l | in epidermal Ihickness of
perilesional skin irealed with betamethasone diproplonale (BU}/treti-
noin or BD/vehicle for 8 weeks. BD/tre(inoin combination (solid bars)
protected against the marked decrease in epidermal thickness eflected
by (he BD/vehicle combination (open barsl ( P = 0-067). Bars arc
means ± SE. n = 16.
Ci t996 British Association of Dermatologists, British journiil of Dermatohtjii. t J5, 6<)-f>4
TRETINOIN AND CORTICOSTEROID-INDUCED ATROPHY 63
WKO
Figure J. Kffects of H weeks Irealment with
belamethiisone dipropionate (BU)/vehide or
BU/tretinoin on epidermal thickness.
Baseline, prelreatmcnt perilesinnal skin
biopsies (week 0) from one palient show
riomiL]! L^piiicrnibil histology unt! Ihickness.
\"[g\n wc't'ks irciitment with liD/vehirle
produces appreciable thinning ol the
epidermi.s Iweek 8K in foiitrast to S weeks
trealment wilh Bl)/tretinoin wliicb protects
against BU-iiidueed epidermal thinning
(week 8). (Haematoxylin and eosin: x 100.)
WKO
dermal thickness decreased (19%) from 50 ± 3 to
41 ± 2 /jm, as compared with a slight, 1%, increase in
epidermal thickness from 47 ± 3 to 48 ± 3^(m, in the
BD/tretinoin sites (P - ()-067. Figs 2 and 3). Thus,
tretinoin partially abrogates epidermal atrophy pro-
duced by topical corticosteroid use.
Stratum corneum was compacted signiticantly from
0 2 ± 0 2 units, at baseline, to 1 5 ± 0 4 units, at week
8. in the BD/tretinoin group, as compared with tio
compaction in the BD/vehicle group, 0 7 ± 0 3 units
at baseline, to 0 2 ± ()• 1 utiits, at the end of treatment
(/' < OOOl). Also, granular layer thickness increased
significantly in the BD/tretinoin group, from 0 7 ± 0 1
to 1 3 i 0 2. as compared with OS ± 0 1 toO 5±OO3.
in the BD/vehicle group (F = OOOl)
y^esiern blot analysis
Owing to three spccimetis not beitig snap frozen,
only 1 3 biopsy samples were available for analysis by
Western blotting. In perilesional skin treated for 8
weeks with BD/vehicle, there was a 55'^ reduction in
pNcoII.from 1211 ± 365 at baseline to 458 ± 161 at 8
weeks. In BD/tretinoin treated skin, there was a lesser.
45%, reduction in pNcoll, from 1178 ± 3 38 at baseline
to 650 ± 208 at 8 weeks (P = 0 07).
Discussion
The combination of topical eortieosteroids and tretinoin
for the treatment of psoriasis is not a new idea. As early
as 1973. it was demonstrated that fluorinated eortieo-
steroids combined with tretinoin-cleared psoriatic
plaques, perhaps with enhanced clinical therapeutic
effect.'' Kaidbey cl al.^ showed that combined therapy
with ()-l% tretinoin and potent topical corticosteroid
was efficacious in psoriasis, but the issue of skin atrophy
was not addressed. We observed no difference in the
speed of resolution nor in the degree ofimprovement of
psoriatic plaques treated with corticosteroid and vehicle,
as compared with plaques treated with corticosteroid
and tretinoin for 8 weeks. We did not observe that the
addition of 0 1% tretinoin increased corticosteroid
efficacy, but this may be because efficacy ofthe cortico-
steroid that we used (BD) may already be very close to.
or at the peak of. the dose-response curve. Thus, it still
remaitis that efficacy of a mild potency topical cortico-
steroid could be enhanced by the addition of tretinoin.
Although we could not demonstrate clinical atrophy
in skin treated with corticosteroid alone, there was both
histological and biochemical evidence that atropby had
occurred. Furthermore, the addition of tretinoin to the
corticosteroid protected, to some extent, against epider-
mal atrophy. The \9% decrease in epidermal thickness
during corticosteroid treatment was similar to that
observed hy Lesnik ct al.~ in the mouse ear model,
where potent topical eortieosteroids thinned the epi-
dermis to two cell layers. In our study, the significant
compaction of stratum corneuin and thickening of
granular layer, with the addition of tretinoin, are
markers of retinoid activity and per se may not be
evidence of a protective effect of tretinoin.
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In addition, we investigated collagen precursor con-
tent in the dermal matrix. It is known from studies in
rats,*^ that triamcinolone diiicetate decreases synthesis
of type I procollagen. in addition to other coilagens.
Furthermore, it has recently been demonstrated that
topical tretinoin can restore synthesis of collagen I in
photoaged human skin,^" and collagen III in photoaged
mouse skin. pNcol I was reduced to a lesser, although
non-significant, extent in the corticosteroid/tretinoin-
treated sites as compared with corticosteroid alone,
implying that topical retinoids may partially abrogate
corticosteroid-induced decreases in collagen synthesis.
Further study is required to prove that it is indeed the
synthesis, and not rale of breakdown, of collagen that is
affected by topical tretinoin.
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